Document is current
Any future updates will be listed below
-
Authors
Desai, Sanjal H. http://orcid.org/0000-0002-7892-2625
Pederson, Levi http://orcid.org/0000-0001-5902-8882
LaPlant, Betsy
Mwangi, Raphael
Maurer, Matthew http://orcid.org/0000-0002-1867-0526
Young, Jason R. http://orcid.org/0000-0001-5351-8266
Macon, William R.
King, Rebecca L. http://orcid.org/0000-0002-7132-0226
Wang, Yucai http://orcid.org/0000-0002-1576-8341
Cerhan, James R. http://orcid.org/0000-0002-7482-178X
Feldman, Andrew http://orcid.org/0000-0001-5009-4808
Inwards, David J.
Micallef, Ivana
Johnston, Patrick
Porrata, Luis F.
Ansell, Stephen M. http://orcid.org/0000-0003-1244-6758
Habermann, Thomas M.
Witzig, Thomas E.
Nowakowski, Grzegorz S. http://orcid.org/0000-0002-6955-9393
- License Information
-
More Information
Article History
Received: 5 January 2022
Revised: 23 February 2022
Accepted: 14 March 2022
First Online: 3 May 2022
Competing interests
: MM: Kite Pharma: Membership on an entity’s Board of Directors or advisory committees; Genentech: Research Funding; Morphosys: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Nanostring: Research Funding; Celgene: Research Funding; Pfizer: Consultancy, Membership on an entity’s Board of Directors or advisory committees. YW: Genentech: Research Funding; Eli Lilly: Membership on an entity’s Board of Directors or advisory committees; Novartis: Research Funding; MorphoSys: Research Funding; InnoCare: Research Funding; Incyte: Membership on an entity’s Board of Directors or advisory committees, Research Funding; LOXO Oncology: Membership on an entity’s Board of Directors or advisory committees, Research Funding; TG Therapeutics: Membership on an entity’s Board of Directors or advisory committees. JRC: Celgene/BMS: Other: Connect Lymphoma Scientific Steering Committee, Research Funding; Regeneron Genetics Center: Other: Research Collaboration; NanoString: Research Funding; Genentech: Research Funding. SMA: Bristol Myers Squibb, ADC Therapeutics, Seattle Genetics, Regeneron, Affimed, AI Therapeutics, Pfizer, Trillium and Takeda: Research Funding. TMH: Seagen: Other: Data Monitoring Committee; Incyte: Other: Scientific Advisory Board; Tess Therapeutics: Other: Data Monitoring Committee; Morphosys: Other: Scientific Advisory Board; Loxo Oncology: Other: Scientific Advisory Board; Eli Lilly & Co.,: Other: Scientific Advisor. TEW: Celgene/BMS, Acerta Pharma, Kura Oncology, Acrotech Biopharma, Karyopharm Therapeutics: Research Funding; Karyopharm Therapeutics, Celgene/BMS, Incyte, Epizyme: Consultancy, Membership on an entity’s Board of Directors or advisory committees. GSN: Celgene, NanoString Technologies, MorphoSys: Research Funding; Celgene, MorphoSys, Genentech, Selvita, Debiopharm Group, Kite/Gilead: Consultancy, Membership on an entity’s Board of Directors or advisory committees. The remaining authors declare no competing interests.
